Role and development of GLP-1 receptor agonists in the management of diabetes

Chee W. Chia, Josephine M. Egan

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Glucagon-like peptide-1 (GLP-1) is a hormone secreted from enteroendocrine L cells of the intestine in response to food. Exogenous GLP-1 administration at pharmacological doses results in many effects that are beneficial for treating type 2 diabetes, these include: (1) an increase in insulin secretion from β cells; (2) a suppression of glucagon secretion from α cells in the presence of hyperglycemia but not hypoglycemia; (3) a delay in gastric emptying and gut motility which in turns delays absorption of ingested nutrients and dampens post-prandial glucose excursion; and (4) an increase in the duration of postprandial satiety therefore suppressing appetite and decreasing food intake which eventually leads to weight loss. However, GLP-1 is subject to rapid enzymatic degradation, and therefore, not suitable for long-term treatment. A synthetic enzyme-resistant GLP-1 receptor agonist that reproduces the biological effects of GLP-1 is in use and more are under development. This review aims at providing a summary of the properties of GLP-1 and the development of GLP-1-based therapies for treatment of diabetes.

Original languageEnglish (US)
Pages (from-to)37-49
Number of pages13
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
StatePublished - 2009
Externally publishedYes


  • Diabetes
  • GLP-1
  • GLP-1R agonist
  • Incretin

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology


Dive into the research topics of 'Role and development of GLP-1 receptor agonists in the management of diabetes'. Together they form a unique fingerprint.

Cite this